honeycomb shape


Welcome to NGM Bio

We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. We are focused on harnessing powerful, untapped biology underlying major diseases to develop transformative therapeutics for patients.

We are intensely science-driven and committed to having a profound impact on addressing some of today’s most urgent medical needs.

right image of girl

We are leveraging our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that will enable us to move rapidly into proof-of-concept studies and deliver first-in-class medicines. We aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs already in clinical development. Our initial areas of focus include cardio-metabolic, liver, oncologic and ophthalmic diseases. But we are not limited to the therapeutic areas we can explore. We intend to continue growing our pipeline of experimental medicines and building our proficiency in discovery research.

Our Team

Our management team, scientists, board members and advisors have extensive track records of successfully discovering, developing and delivering to patients multiple, class-defining drugs with meaningful clinical and commercial impact, which positions us well to maximize the potential of our drug discovery approach.

William J. Rieflin

Executive Chairman

David J. Woodhouse, Ph.D.

Chief Executive Officer and Acting Chief Financial Officer

Aetna Wun Trombley, Ph.D.

President and Chief Operating Officer

Jin-Long Chen, Ph.D.

Founder and Chief Scientific Officer

Alex DePaoli, M.D.

Senior Vice President, Chief Medical Officer

Marc Learned, Ph.D.

Vice President, Research Operations

Wenyan (David) Shen, Ph.D.

Senior Vice President, Biologics and CMC

Hui Tian, Ph.D.

Senior Vice President, Research

Board of Directors

William J. Rieflin

Executive Chairman, NGM Biopharmaceuticals

David V. Goeddel, Ph.D.

Managing Partner, The Column Group

Jin-Long Chen, Ph.D.

Founder and Chief Scientific Officer, NGM Biopharmaceuticals

Suzanne Sawochka Hooper

Executive Vice President and General Counsel, Jazz Pharmaceuticals

Mark Leschly

Managing Partner, RHO Capital Partners

David Schnell, M.D.

Managing Director, Prospect Venture Partners

Peter Svennilson

Managing Partner, The Column Group

McHenry (Mac) T. Tichenor, Jr.

Managing Partner, Tichenor Ventures, LLC

David J. Woodhouse, Ph.D.

Chief Executive Officer and Acting Chief Financial Officer, NGM Biopharmaceuticals

Scientific Advisory Board

Michael S. Brown, M.D.


Michael Fischbach, Ph.D.

K. Christopher Garcia, Ph.D.

Joseph L. Goldstein, M.D.

Robert D. Schreiber, Ph.D.

Special Advisors

Grant Heidrich

Jeff Jonker

Arthur D. Levinson, Ph.D.

NGM-Merck Collaboration

In 2015, Merck and NGM entered into a broad multi-year strategic collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. In addition to a $94 million upfront payment and purchase of $106 million of NGM’s preferred stock, Merck committed up to $250 million to fund NGM’s research and development efforts under the initial five-year term of the collaboration, with the potential for additional funding if certain conditions are met. Merck has the option to extend the research agreement for two additional two-year terms. 

The collaboration includes an exclusive worldwide license to NGM’s growth differentiation factor 15, or GDF15, program. Merck has a one-time option to license all resulting collaboration programs following human proof of concept trials. Upon exercising such options, Merck will lead global product development and commercialization for the resulting products, if approved. Prior to Merck initiating a Phase 3 study for a licensed program, NGM may elect to either receive milestone and royalty payments or, in certain cases, to co-fund development and participate in a global cost and revenue share arrangement of up to 50%. The agreement also provides NGM with the option to participate in the co-promotion of any co-funded program in the United States.

NGM’s fibroblast growth factor 19, or FGF19, program, including NGM282, is excluded from the agreement and remains wholly owned by NGM.